Formulary Update
The following actions were taken by the Pharmacy and Therapeutics Committee at their meeting on 6/22/01:
Bismuth subgallate epinephrine (BSE) paste, a compounded topical hemostatic agent, was added to the Formulary for the control of bleeding after adenotonsillectomy.
Tolterodine LA (Detrol LA®) was added to the Formulary for the control of overactive bladder. Oxybutynin XL (Ditropan XL®) was rejected.
A request for the addition of a leuprolide acetate implant (Viadur®) was rejected because the product lacks significant advantages over the 4 month depot injection.
Valganciclovir (Valcyte®) was added for the management of CMV retinitis.
Pediatr Pharm. 2001;7(7) © 2001 Children's Medical Center, University of Virginia
Comments